本帖最后由 老马 于 2013-3-13 13:43 编辑 5 s6 Z5 } o- w/ R% q. Z, J
' y2 B9 H& G$ |/ I' x3 v
健择（吉西他滨）+顺铂+阿瓦斯汀
7 F1 A6 ]% n5 ~6 M# { Gemzar +Cisplatin + Avastin
: ^: g0 ]4 V& H7 X: [/ \http://annonc.oxfordjournals.org/content/21/9/1804.full9 \. y2 ^( r, X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* x: u9 O. b' GPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. / |7 F$ E4 O. p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 @% t h9 E' r6 C1 a; B* ?) }
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 846)
4 r+ [+ H/ ^7 E$ Z. }
华为网盘附件：$ W# n# I5 N n8 Y
【华为网盘】ava.JPG8 a# A( n0 _! S0 ^
|
肺腺癌术后一年复查，这是复发转移了
【基本病情：2024年4月底确诊肺癌，五月初手术，术后分期3A期，肺腺癌，淋巴结转移，
求助，请大家帮忙看看，是不是耐药了
51岁，男，肺鳞癌IV期，2024年8月第一次化疗免疫联合治疗（白紫+顺铂+信迪利单抗），
家人去世，剩9瓶倍瑞搏，付邮赠送
已出
妈妈去世，家里还有9瓶倍瑞搏，保质期到7月19日，付邮费赠送。有需要的病友可以
杏林手记丨为一种可能
作者：博雅
一天深夜，朋友的孩子跟我聊天。
朋友的孩子在我的建议下学了医，大四，马
求助 K药和替雷利珠如何选择
父亲9月刚查出非小细胞低分化癌伴随左肾上腺和第10胸椎转移PDL1高表达(TPS=90%) SMARC
显身卡
